SEARCH

SEARCH BY CITATION

References

  • Bernard, G.R., Vincent, J.L., Laterre, P.F., LaRosa, S.P., Dhainaut, J.F., Lopez-Rodriguez, A., Steingrub, J.S., Garber, G.E., Helterbrand, J.D., Ely, E.W. & Fisher, C.J. Jr, for the Recombinant Human-activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine, 344, 699709.
  • Brugge, J.M., Simioni, P., Bernardi, F., Tormene, D., Lunghi, B., Tans, G., Pagnan, A., Rosing, J. & Castoldi, E. (2005) Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. Journal of Thrombosis and Haemostasis, 3, 26952702.
  • Cortellaro, M., Boschetti, C., Cofrancesco, E., Zanussi, C., Catalano, M., De Gaetano, G., Gabrielli, L., Lombardi, B., Specchia, G. & Tavazzi, L. (1992) The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arteriosclerosis, Thrombosis and Vascular Biology, 12, 10631070.
  • Creasey, A.A. & Reinhart, K. (2001) Tissue factor pathway inhibitor activity in severe sepsis. Critical Care Medicine, 29(Suppl. 7), S126S129.
  • Curvers, J., Thomassen, M.C., Nicolaes, G.A., Van Oerle, R., Hamulyak, K., Hemker, H.C., Tans, G. & Rosing, J. (1999) Acquired APC resistance and oral contraceptives: differences between two functionals tests. British Journal of Haematology, 105, 8894.
  • Curvers, J., Thomassen, M.C., Rimmer, J., Hamulyak, K., Van Der Meer, J., Tans, G., Preston, F.E. & Rosing, J. (2002) Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thrombosis and Haemostasis, 88, 511.
  • Dahlbäck, B., Carlsson, M. & Svensson, P.J. (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the United States of America, 90, 10041008.
  • Derhaschnig, U., Reiter, R., Knöbl, P., Baumgartner, M., Keen, P. & Jilma, B. (2003) Recombinant human activated protein C (rhAPC, drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood, 102, 20932098.
  • Dhainaut, J.F., Yan, S.B., Cariou, A. & Mira, J.-P. (2002) Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Critical Care Medicine, 30(Suppl. 5), S318S324.
  • Duchemin, J., Pittet, J., Tartary, M., Beguin, S., Gaussem, P., Athen-Gelas, M. & Aiach, M. (1994) A new method based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thrombosis and Haemostasis, 71, 331338.
  • Esmon, C. (2000) The protein C pathway. Critical Care Medicine, 28(Suppl. 9), S44S48.
  • Esmon, C.T. (2003) The protein C pathway. Chest, 124, 26S32S.
  • Esmon, C.T. (2004) Crosstalk between inflammation and thrombosis. Maturitas, 47, 305314.
  • Folsom, A.R., Cushman, M., Tsai, M.Y., Aleksic, N., Heckbert, S.R., Boland, L.L., Tsai, A.W., Yanez, N.D. & Rosamond, W.D. (2002) A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood, 99, 27202725.
  • Garcia de Frutos, P., Alim, R.I., Härdig, Y., Zöller, B. & Dahlbäck, B. (1994) Differential regulation of alpha and beta chains of C4b-binding protein during acute phase response resulting in stable plasma levels of free anticoagulant protein S. Blood, 84, 815822.
  • Gorog, D.A., Rakhit, R., Parums, D., Laffan, M. & Davies, G.J. (1998) Raised factor VIII is associated with coronary thrombotic events. Heart, 80, 415417.
  • Hemker, H.C., Willems, G.M. & Beguin, S. (1986) A computer-assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thrombosis and Haemostasis, 56, 917.
  • Henkens, C.M., Bom, V.J. & Van Der Meer, J. (1995) Lowered APC-sensitivity ratio related to increased factor-VIII clotting activity. Thrombosis and Haemostasis, 74, 11981199.
  • De Jonge, E., Dekkers, P.E., Creasey, A.A., Hack, C.E., Paulson, S.K., Karim, A., Kesecioglu, J., Levi, M., Van Deventer, S.J. & Van Der Poll, T. (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood, 95, 11241129.
  • Kerlin, B.A., Yan, S.B., Isermann, B.H., Brandt, J.T., Sood, R., Basson, B.R., Joyce, D.E., Weiler, H. & Dhainaut, J.F. (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood, 102, 30853092.
  • Koppelman, S.J., Hackeng, T.M., Sixma, J.J. & Bouma, B.N. (1995) Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood, 86, 10621071.
  • Nicolaes, G.A., Thomassen, M.C., Tans, G., Rosing, J. & Hemker, H.C. (1997) Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagulation and Fibrinolysis, 8, 2838.
  • Nijziel, M.R., Van Oerle, R., Thomassen, M.C., Van Pampus, E.C., Hamulyak, K., Tans, G. & Rosing, J. (2003) Acquired resistance to activated protein C in breast cancer patients. British Journal of Haematology, 120, 117122.
  • Paspatis, G.A., Sfyridaki, A., Papanikolaou, N., Triantafyllou, K., Livadiotaki, A., Kapsoritakis, A. & Lydataki, N. (2002) Resistance to activated protein C, factor V Leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiology of Haemostasis and Thrombosis, 32, 27.
  • De Pont, A.C., Moons, A.H., De Jonge, E., Meijers, J.C., Vlasuk, G.P., Rote, W.E., Büller, H.R., Van Der Poll, T. & Levi, M. (2004) Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. Journal of Thrombosis and Haemostasis, 2, 6570.
  • Reitsma, P.H., Branger, J., Den Blink, B., Weijer, S., Van Der Poll, T. & Meijers, J.C. (2003) Procoagulant protein levels are differentially increased during human endotoxemia. Journal of Thrombosis and Haemostasis, 1, 10191023.
  • Rodeghiero, F. & Tosetto, A. (1999) Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Annals of Internal Medicine, 130, 643650.
  • De Ronde, H. & Bertina, R.M. (1994) Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thrombosis and Haemostasis, 72, 880886.
  • Sandset, P.M., Abildgaard, U. & Pettersen, M. (1987) A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thrombosis Research, 47, 389400.
  • Tans, G., Van Hylckama Vlieg, A., Thomassen, M.C., Curvers, J., Bertina, R.M., Rosing, J. & Rosendaal, F.R. (2003) Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. British Journal of Haematology, 122, 465470.
  • De Visser, M.C., Rosendaal, F.R. & Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 12711276.
  • De Visser, M.C., Van Hylckama Vlieg, A., Tans, G., Rosing, J., Dahm, A.E., Sandset, P.M., Rosendaal, F.R. & Bertina, R.M. (2005) Determinants of the APTT- and ETP-based APC sensitivity tests. Journal of Thrombosis and Haemostasis, 3, 14881494